Melinda Magyari, MD, PhD, consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, discusses the current body of data on treating pediatric multiple sclerosis (MS).
Melinda Magyari, MD, PhD, consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, discusses the current body of data on treating pediatric multiple sclerosis (MS).
Transcript
How good is our current body of data on treating pediatric MS?
Because there have not been randomized control trials, only a few of them in pediatric-onset MS, the current evidence is not very strong. Randomized controlled trials exclude patients younger than 18 years. So I would, and as you can see in my presentation, most of the patients have been treated with intramuscular interferons. So the body of evidence on that treatment is rather good. But we need more observational data. We need large cohorts, maybe to merge them. Because the data is there, we just have to provide evidence.
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Distinguishing Biomarkers Identified in MS Outcomes
March 19th 2024Results from this cohort study found that levels of glial fibrillary acid protein, cerebral spinal fluid, and neurofilament heavy chain are distinguishable biomarkers that are associated with disease outcomes in multiple sclerosis (MS).
Read More
FDA Issues CRL for Glatiramer Acetate Depot for Relapsing Forms of MS
March 11th 2024The FDA has declined to approve glatiramer acetate (GA) depot in the treatment of relapsing types of multiple sclerosis (MS), issuing a complete response letter (CRL) for the long-acting, injectable form of GA.
Read More
Getting to Know Dr Fabiola Molina, Hospitalist
February 26th 2024Fabiola Molina, MD, MHS, is a practicing hospitalist and assistant professor of medicine at Yale School of Medicine and Yale New Haven Hospital. An immigrant from Mexico, her experiences straddling 2 worlds, while attempting to navigate with her family the complicated safety-net system for health care in Texas, were key influences to her ardent focus on health equity.
Read More